Development Of A Diagnostic Test For Bipolar Disorder (BD)
Funder
National Health and Medical Research Council
Funding Amount
$140,330.00
Summary
A unique test that monitors the rate of switching between the hemispheres of the brain in response to visual stimuli has been devised. A patent application covers an apparatus and test to measure the switching rate between the hemispheres and the way in which such measurements can be used as a means to diagnose bipolar disorder (BD). BD, also called manic depression, is a form of depression that currently affects over six million people worldwide with about three million in the USA alone. The co ....A unique test that monitors the rate of switching between the hemispheres of the brain in response to visual stimuli has been devised. A patent application covers an apparatus and test to measure the switching rate between the hemispheres and the way in which such measurements can be used as a means to diagnose bipolar disorder (BD). BD, also called manic depression, is a form of depression that currently affects over six million people worldwide with about three million in the USA alone. The condition has phases of mania and depression and periods of remittance. Full cycles of BD can occur as many as three times a year and for many patients, this is a lifelong condition. BD is effectively treated, once it is diagnosed. It is estimated that 20% of sufferers go undiagnosed and many more are misdiagnosed. The cost of mis- or non-diagnosis is measured by suicides, the financial burden on society with health care, loss of productivity etc, effects on family and associates, crime, etc. Diagnosis to date is achieved mainly by subjective means such as questionnaires. These instruments do not conclusively separate BD from other forms of depression and schizophrenia, for which treatment is quite different. Nor do they allow for factors such as substance abuse and other medical conditions that the patient may be suffering. BD is hereditary with the slow hemispheric switch rate being an indicator of the genetic trait. This phenomenon allows for an objective test for BD, even if an individual has not had an episode of BD. The slow switch allows relatively easy separation of a BD patient from those exhibiting symptoms that may have other causes.Read moreRead less
A Novel Non-invasive Diagnostic Imaging Technique Of Metastatic Cancer Using Plasminogen Activator Inhibitor Type 2.
Funder
National Health and Medical Research Council
Funding Amount
$187,750.00
Summary
This project aims to develop a non-invasive tumour diagnostic imaging agent based on a non-toxic protein (PAI2) that we know specifically identifies a critical marker of malignancy. PAI2 will be labelled with commonly used imaging radioisotopes. This novel imaging technique has important potential clinical uses including, determination of the most appropriate treatment for individual patients, assessing the success of such treatments, and a novel non-invasive prognostic indicator of malignancy.
The Development Of Novel, Biofilm-resistant Biomaterials
Funder
National Health and Medical Research Council
Funding Amount
$147,360.00
Summary
Almost all patients who are catheterised long term develop a bacterial infection. Most often, the infection is the result of colonisation of the catheter surface by bacteria. Bacterial colonisation of the surface of biomedical devices represents a significant health threat as such bacterial biofilms are extremely resistant to traditional antibiotic regimens. This project aims to develop novel materials that prevent bacterial colonisation on catheters and other biomedical related devices. Our tec ....Almost all patients who are catheterised long term develop a bacterial infection. Most often, the infection is the result of colonisation of the catheter surface by bacteria. Bacterial colonisation of the surface of biomedical devices represents a significant health threat as such bacterial biofilms are extremely resistant to traditional antibiotic regimens. This project aims to develop novel materials that prevent bacterial colonisation on catheters and other biomedical related devices. Our technology is based on compounds identified from a marine alga that prevent bacterial colonisation of its surface. Similarly, we have shown that these compounds, when coated onto test surfaces, prevent bacterial colonisation of a range of materials.Read moreRead less
Application Of Follistatin To The Resolution Of Liver Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$330,990.00
Summary
Liver fibrosis or scarring is a consequence of a number of diseases, leading eventually to extensive damage known as cirrhosis. It is a significant health problem both here in Australia and overseas with around 180,000 patients diagnosed each year in the Western world. Cirrhosis arises from many causes, two major groups being patients who contract hepatitis and alcoholics. People with cirrhosis have a much increased risk of liver failure, which requires liver transplantation, or of developing li ....Liver fibrosis or scarring is a consequence of a number of diseases, leading eventually to extensive damage known as cirrhosis. It is a significant health problem both here in Australia and overseas with around 180,000 patients diagnosed each year in the Western world. Cirrhosis arises from many causes, two major groups being patients who contract hepatitis and alcoholics. People with cirrhosis have a much increased risk of liver failure, which requires liver transplantation, or of developing liver cancer, for which current treatments have limited success. We have been studying two proteins, activin and follistatin, both of which are made in the liver. We are interested in activin because it is one of the body's mechanisms to control cell growth, and also seems to stimulate the development of scar tissue. Follistatin is the natural inhibitory substance for activin. It blocks the effects of activin and helps promote cell growth in the liver. We believe that follistatin may also be useful in controlling liver scarring. This process will be studied in animal models of cirrhosis, in the hope that follistatin treatment will reduce the level of liver damage. If successful, this would be important information that would enable us to design treatments applicable to human sufferers of these liver diseases. In another part of the project, we will assess whether activin and follistatin might be useful markers of liver disease. Most patients require a liver biopsy to assess the amount of liver damage, and a simple blood test would be a far easier, less traumatic and cheaper alternative.Read moreRead less
A New Non-invasive Diagnostic Technique Based On Detection Of Exhaled Respiratory Pathogens.
Funder
National Health and Medical Research Council
Funding Amount
$179,300.00
Summary
We developed a special collection mask and showed that the breath of people with colds or flu contains a tiny amount of virus. Currently, diagnostic samples are collected by putting a tube into the airways - this is very uncomfortable. Our masks may provide a new and more comfortable way to diagnose lung infections. We want to build better masks and ways to detect viruses and bacteria to test out this method. This may create a new test that will improve diagnosis and treatment.
Pre-clinical Assessment Of Novel Growth Factor Complexes As A Topical Agent In The Treatment Of Deep
Funder
National Health and Medical Research Council
Funding Amount
$156,870.00
Summary
Healing of deep burns, unlike that of superficial injuries, often resolves with scarring. Scarring is reduced with rapid closure of burns. The CIs have discovered and patented novel growth factor complexes that stimulate the growth and migration of keratinocytes, cells derived from skin. Hence these complexes hold therapeutic potential for wounds that require rapid closure such as deep burns. This application will provide pre-clinical, proof-of-principle data to facilitate future patient trials.
Web-based Multimedia Information Management System For Use In Remote Diagnosis Of Eye Diseases
Funder
National Health and Medical Research Council
Funding Amount
$196,000.00
Summary
Our aim is to develop a web-based multimedia information management system for use in remote diagnosis of eye diseases. The proposed system will provide medical advice and diagnosis, information and distance education for those working in health care as well as the community, computer-aided diagnosis and assistance in the operational and medical decision-making process. Less expensive health care personnel should be able to use the system with little training in remote and rural areas. Significa ....Our aim is to develop a web-based multimedia information management system for use in remote diagnosis of eye diseases. The proposed system will provide medical advice and diagnosis, information and distance education for those working in health care as well as the community, computer-aided diagnosis and assistance in the operational and medical decision-making process. Less expensive health care personnel should be able to use the system with little training in remote and rural areas. Significantly, the project should empower remote general doctors and nurses by proper access to expert advice, save many remote patients from unnecessary visits to specialist centres on the one hand and allow more proper diagnosis and intervention on the other. It has the potential for significant reductions in the cost of health care delivery, should strengthening the bond between medical services in remote and city areas, provide training and education of local GPs, nurses, health care workers and optometrists and provide web-based disease management systems will provide instant access to health care information. The outcomes of this project are potentially of great significance to remote and rural communities in Australia and around the world. There will be an enormous impact on current health care practices. Significantly, the project should empower remote general doctors and nurses by proper access to expert advice, save many remote patients from unnecessary visits to specialist centres on the one hand and allow more proper diagnosis and intervention on the other. It has the potential for significant reductions in the cost of health care delivery, should strengthening the bond between medical services in remote and city areas, provide training and education of local GPs, nurses, health care workers and optometrists and provide web-based disease management systems will provide instant access to health care information. The outcomes of this project are potentially of great significance to remote and rural communities in Australia and around the world. There will be an enormous impact on current health care practices.Read moreRead less
Therapeutic Strategies And Screening Methods For PKC Epsilon Antagonists In The Treatment Of Type 2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$157,375.00
Summary
Type 2 diabetes is a chronic disease affecting over a million Australians and hundreds of millions of people worldwide. Its prevalence is rising due to several factors such as an increase in caloric intake, the aging of the population, and the common sedentary lifestyle of Western civilization. Type 2 diabetes occurs when the pancreas is unable to produce enough insulin for the body to cope with rising blood glucose levels after a meal, and has been strongly linked to obesity. We have now shown ....Type 2 diabetes is a chronic disease affecting over a million Australians and hundreds of millions of people worldwide. Its prevalence is rising due to several factors such as an increase in caloric intake, the aging of the population, and the common sedentary lifestyle of Western civilization. Type 2 diabetes occurs when the pancreas is unable to produce enough insulin for the body to cope with rising blood glucose levels after a meal, and has been strongly linked to obesity. We have now shown that an enzyme found in the pancreas becomes inappropriately activated under conditions of fat oversupply, and plays an important role in the development of defects in insulin release from the pancreas in response to glucose. Excitingly, we have also shown that inhibition of this enzyme can partly reverse these defects once they have been established. We now intend to further validate this enzyme as a drug target by determining the optimum dosing regimen for the treatment of type 2 diabetes in a mouse model, and testing whether this approach can be used in conjunction with previously-developed drugs which promote insulin action, to improve bood glucose handling better than either treatment alone. This would promote the enzyme as a therapeutic strategy in the treatment of Type 2 diabetes. We also plan to develop a high throuhput screen to identify novel inhibitors of the enzyme, which will further increase the attractiveness of the project to pharmaceutical companies, who are better able to implent full commercialization of our findings.Read moreRead less